Limiflex is a device for grade 1 lumbar degenerative spondylolisthesis patients with spinal stenosis, according to a Feb. 1 news release. It’s designed to preserve motion and stability after an open lumbar decompression.
Three key milestones:
1. Limiflex received FDA breakthrough device designation, providing the company with expedited review timelines and increased communication with the agency.
2. Empirical Spine began its premarket approval for Limiflex. The first module was submitted, and the remaining two will be added in the coming months.
3. Outcomes from an investigational device study were presented in November. The study concluded Limiflex showed similar improvement in disability compared to those who had a transforaminal lumbar interbody fusion.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
